At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NEUP Neuphoria Therapeutics Inc
Post-Mkt 12-11 18:36:51 EST
3.98
-0.23
-5.46%
盘后4.12
+0.14+3.52%
17:21 EST
High4.38Low3.95Vol341.15K
Open4.28D1 Closing4.21Amplitude10.10%
Mkt Cap21.40MTradable Cap15.39MTotal Shares5.38M
T/O1.40MT/O Rate8.82%Tradable Shares3.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Leading Proxy Advisory Firm Iss Recommends That Shareholders Vote the White Proxy Card for Both of Neuphoria’s Director Nominees
THOMSON REUTERS  ·  12-08
Leading Proxy Advisory Firm Iss Recommends That Shareholders Vote the White Proxy Card for Both of Neuphoria’s Director Nominees
Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Dow Jones  ·  12-08
Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Neuphoria Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $7 From $21
THOMSON REUTERS  ·  12-05
Neuphoria Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $7 From $21
Neuphoria Therapeutics Inc - Lynx1's New Bid Lower Than Initial $4.75 per Share
THOMSON REUTERS  ·  12-04
Neuphoria Therapeutics Inc - Lynx1's New Bid Lower Than Initial $4.75 per Share
Neuphoria Therapeutics Inc - Pauses R&D Expenditures for Bnc210 in Ptsd & Is Evaluating All Possibilities as Part of the Co's Strategic Review
THOMSON REUTERS  ·  12-04
Neuphoria Therapeutics Inc - Pauses R&D Expenditures for Bnc210 in Ptsd & Is Evaluating All Possibilities as Part of the Co's Strategic Review
Neuphoria Therapeutics Inc - Received Substantial Competing Indications of Interest
THOMSON REUTERS  ·  12-04
Neuphoria Therapeutics Inc - Received Substantial Competing Indications of Interest
Neuphoria Therapeutics Inc - Urges Stockholders to Vote "for" Both of Neuphoria's Nominees on White Proxy Card
THOMSON REUTERS  ·  12-04
Neuphoria Therapeutics Inc - Urges Stockholders to Vote "for" Both of Neuphoria's Nominees on White Proxy Card
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
GlobeNewswire  ·  12-04
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
Lynx1 Capital Management Lp Says on Dec 2, Deliveres Letter to Neuphoria Therapeutics' Board - SEC Filing
THOMSON REUTERS  ·  12-02
Lynx1 Capital Management Lp Says on Dec 2, Deliveres Letter to Neuphoria Therapeutics' Board - SEC Filing
Lynx1 Capital Management - Letter to Neuphoria Therapeutics Contains Non-Binding Proposal to Buy Co's Outstanding Shares for $4.75/Share in Cash
THOMSON REUTERS  ·  12-02
Lynx1 Capital Management - Letter to Neuphoria Therapeutics Contains Non-Binding Proposal to Buy Co's Outstanding Shares for $4.75/Share in Cash
Press Release: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Dow Jones  ·  12-01
Press Release: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Neuphoria Therapeutics: Strategic Review Process Is Well Underway
THOMSON REUTERS  ·  11-24
Neuphoria Therapeutics: Strategic Review Process Is Well Underway
Neuphoria Therapeutics Faces Proxy Battle as Dissident Investor Nominates Rival Directors
Reuters  ·  11-24
Neuphoria Therapeutics Faces Proxy Battle as Dissident Investor Nominates Rival Directors
Lynx1 Capital Management Lp - Withdraws Previous Non-Binding Proposal to Acquire Neuphoria Therapeutics - SEC Filing
THOMSON REUTERS  ·  11-18
Lynx1 Capital Management Lp - Withdraws Previous Non-Binding Proposal to Acquire Neuphoria Therapeutics - SEC Filing
BRIEF-Neuphoria Therapeutics May Offer & Sell Common Stock Of Up To $20 Million From Time To Time - SEC Filing
Reuters  ·  11-15
BRIEF-Neuphoria Therapeutics May Offer & Sell Common Stock Of Up To $20 Million From Time To Time - SEC Filing
Neuphoria Therapeutics Inc - May Offer & Sell Common Stock of up to $20 Mln From Time to Time - SEC Filing
THOMSON REUTERS  ·  11-15
Neuphoria Therapeutics Inc - May Offer & Sell Common Stock of up to $20 Mln From Time to Time - SEC Filing
BRIEF-Neuphoria Announces Initiation Of Strategic Review
Reuters  ·  11-11
BRIEF-Neuphoria Announces Initiation Of Strategic Review
Neuphoria Therapeutics: Confirms Receipt of Unsolicited Indication of Interest and Director Nominations From Lynx1 Master Fund Lp
THOMSON REUTERS  ·  11-11
Neuphoria Therapeutics: Confirms Receipt of Unsolicited Indication of Interest and Director Nominations From Lynx1 Master Fund Lp
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
THOMSON REUTERS  ·  11-11
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
Neuphoria Therapeutics Inc - on Nov 10, Lynx1 Master Fund Offers $5.20 per Share in Cash for Neuphoria
THOMSON REUTERS  ·  11-11
Neuphoria Therapeutics Inc - on Nov 10, Lynx1 Master Fund Offers $5.20 per Share in Cash for Neuphoria

Introduction

Company Name.
Neuphoria Therapeutics Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--